A few hours after I had written this post about the Pfizer/Esperion spin-off signaling a changing of the times in big pharma, I see I this story about Bristol-Myers Squibb divesting ConvaTec to some private equity groups (Nordic Capital VII and Avista Capital Partners) for $4.1 billion dollars. This press release jogged my memory and I remembered reading about BMS divesting its medical imaging division for 500 something million, also to Avista sometime in late December. While neither deal is applicable to my “entering a new R&D phase” projection I put forth in the aforementioned post, the move does still signify the big players’ willingness to concentrate on what they do best.
Now, I don’t follow non-biopharma industries real closely so you can correct me if I’m wrong, but doesn’t this seem to be the anti-GE strategy (i.e.; divesting non-synergistic business units)? I’m not sure what this means. Maybe pharma is choosing potential growth rate over mitigating risk by diversification for a potential larger return? Or, contrary to my thesis, big pharma may just be trading a failed (or stagnant) asset for one with a brighter future by buying the next hot commodity. With licensing deals for in-demand, phase 2 compounds increasingly in the 100-200m upfront, $1b biodollar every dime helps (even if you have 11 figures of cash in the bank.








Add New Comment
Viewing 2 Comments
Thanks. Your comment is awaiting approval by a moderator.
Do you already have an account? Log in and claim this comment.
Do you already have an account? Log in and claim this comment.
Do you already have an account? Log in and claim this comment.
Add New Comment
Trackbacks
(Trackback URL)
May 6, 2008 at 8:37 am
[...] a previous post, I speculated on reasons for shedding of non-core pharmaceutical assets by BMS. Don’t read [...]